Kempharm Stock Financials

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Understanding current and past Kempharm Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kempharm's financial statements are interrelated, with each one affecting the others. For example, an increase in Kempharm's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Kempharm's financials over time to get the whole picture. Kempharm Invested Capital is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital was reported at 69.7 Million. The current Invested Capital Average is estimated to increase to about 20.1 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (8.3 M).
Please make use of Kempharm fundamental data analysis to find out if markets are presently mispricing the entity. We were able to interpolate data for thirty-five available fundamentals for Kempharm, which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Kempharm financials, including its price to book, current ratio, working capital, as well as the relationship between the net income and number of employees . Given that Kempharm has a number of shares shorted of 3.55 M, we recommend you to check Kempharm last-minute market performance to make sure the company can sustain itself down the road. Use Kempharm to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Kempharm to be traded at $10.32 in 90 days.

Search Fundamentals 

 
Refresh
With this module, you can analyze Kempharm financials for your investing period. You should be able to track the changes in Kempharm individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  Chance Of Financial Distress
Less than 3
Kempharm has less than 3 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Kempharm stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Kempharm's official financial statements usually reflect Kempharm's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kempharm. For example, before you start analyzing numbers published by Kempharm accountants, it's critical to develop an understanding of what Kempharm's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kempharm's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kempharm's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kempharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kempharm. Please utilize our Beneish M Score to check the likelihood of Kempharm's management to manipulate its earnings.

Kempharm Company Summary

Kempharm competes with Denali Therapeutics, Design Therapeutics, Precision Biosciences, and Dynavax Technologies. KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP488445206
Older SymbolKMPHD
LocationFlorida; U.S.A
Business Address1180 Celebration Boulevard
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitekempharm.com
Phone321 939 3416
CurrencyUSD - US Dollar

Kempharm Key Financial Ratios

Generally speaking, Kempharm's financial ratios allow both analysts and investors to convert raw data from Kempharm's financial statements into concise, actionable information that can be used to evaluate the performance of Kempharm over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Kempharm reports annually and quarterly.

Kempharm Key Balance Sheet Accounts

201620172018201920202021 (projected)
Total Assets84.89 M52.46 M26.75 M10.51 M11.21 M11.5 M
Current Assets74.36 M45.9 M23.72 M6.97 M8.38 M8.6 M
Assets Non Current10.53 M6.56 M3.02 M3.54 M2.83 M3.72 M
Cash and Equivalents17.86 M11.97 M19.12 M3.56 M4.32 M4.44 M
Total Debt91.98 M93.48 M82.05 M79.53 M70.35 M70.48 M
Debt Current157 K3.52 M3.55 M284 K717 K735.87 K
Debt Non Current91.83 M89.96 M78.5 M79.24 M69.64 M68.92 M
Shareholders Equity(18.7 M)(57.52 M)(66.57 M)(74.46 M)(66.41 M)(71.66 M)
Total Liabilities103.58 M109.97 M93.31 M84.96 M77.62 M82.85 M
Current Liabilities6.64 M11.51 M12 M5.43 M7.54 M8.35 M

Kempharm Key Income Statement Accounts

201620172018201920202021 (projected)
Consolidated Income(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Earning Before Interest and Taxes EBIT(11.02 M)(37.65 M)(51.12 M)(19.69 M)(8.01 M)(8.64 M)
Earning Before Interest and Taxes USD(11.02 M)(37.65 M)(51.12 M)(19.69 M)(8.01 M)(8.64 M)
Interest Expense5.51 M5.78 M5.47 M4.86 M4.79 M4.75 M
Net Income(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Net Income Common Stock(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Net Income Common Stock USD(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Operating Expenses37.48 M33.37 M55.9 M33.18 M18.9 M26.07 M
Operating Income(37.48 M)(33.37 M)(55.9 M)(20.34 M)(5.61 M)(6.05 M)
Research and Development Expense20.47 M20.59 M41.76 M19.41 M8.84 M9.08 M
Selling General and Administrative Expense14 M12.77 M12.51 M10.82 M7.92 M9.44 M
Weighted Average Shares912.32 K915.81 K1.12 M1.85 M3.98 M4.3 M
Weighted Average Shares Diluted912.32 K915.81 K1.12 M1.85 M3.98 M4.3 M
Income Tax Expense26 K(15 K)(43 K)(126 K)(34 K)(36.68 K)

Kempharm Key Cash Accounts

201620172018201920202021 (projected)
Capital Expenditure(643 K)(181 K)(21 K)(26 K)(33 K)(35.61 K)
Depreciation Amortization and Accretion175 K336 K324 K304 K273 K262.3 K
Net Cash Flow or Change in Cash and Cash Equivalents(14.46 M)(5.89 M)7.15 M(15.56 M)767 K827.55 K
Issuance Repayment of Debt Securities62.17 M(157 K)(193 K)4.94 M2.82 M2.9 M
Net Cash Flow from Financing61.16 M(203 K)28.02 M4.94 M2.74 M2.81 M
Net Cash Flow from Investing(45.85 M)27.41 M33.33 M3.23 M(33 K)(35.61 K)
Net Cash Flow Investment Acquisitions and Disposals(45.2 M)27.59 M33.35 M3.26 M3.75 M4.04 M
Net Cash Flow from Operations(29.77 M)(33.1 M)(54.2 M)(23.74 M)(1.94 M)(2.09 M)
Share Based Compensation6.6 M4.56 M6.5 M4.41 M2.49 M3.28 M

Kempharm Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kempharm's current stock value. Our valuation model uses many indicators to compare Kempharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kempharm competition to find correlations between indicators driving Kempharm's intrinsic value. More Info.
Kempharm is rated fourth overall in shares owned by institutions category among related companies. It is rated fourth overall in current asset category among related companies fabricating about  3,373,550  of Current Asset per Shares Owned by Institutions. . The current Current Assets is estimated to increase to about 8.6 M. The current Average Assets is estimated to increase to about 11.2 M

Kempharm Systematic Risk

Kempharm's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kempharm volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was sixty with a total number of output elements of one. The Beta measures systematic risk based on how returns on Kempharm correlated with the market. If Beta is less than 0 Kempharm generally moves in the opposite direction as compared to the market. If Kempharm Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kempharm is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kempharm is generally in the same direction as the market. If Beta > 1 Kempharm moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Kempharm Financials

What exactly are Kempharm Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Kempharm's income statement, its balance sheet, and the statement of cash flows. Potential Kempharm investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Kempharm investors may use each financial statement separately, they are all related. The changes in Kempharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kempharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2018 2019 2020 2021 (projected)
Current Assets23.72 M6.97 M8.38 M8.6 M
Total Assets26.75 M10.51 M11.21 M11.5 M

Kempharm July 29, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Kempharm help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kempharm. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kempharm based on widely used predictive technical indicators. In general, we focus on analyzing Kempharm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kempharm's daily price indicators and compare them against related drivers.
Downside Deviation3.77
Information Ratio0.0747
Maximum Drawdown17.42
Value At Risk(6.42)
Potential Upside6.15
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.